# BioStem secures access to $40 million equity facility

_Published Sunday, September 20, 2026 at 8:16 PM EDT · Capital, Products · Latest · Tier 2 — Notable_

BioStem Technologies entered a common-stock purchase agreement giving it the option to sell Roth Principal Investments up to $40 million of shares over 36 months. BioStem controls the timing and amount of any sales, while purchase prices would be set at 97% of the applicable volume-weighted average price for market-open and intraday purchases and 95% for pre- and post-market purchases.

The company registered up to 12,050,000 shares for resale. Issuing all of them would equal approximately 40.2% of BioStem's outstanding stock as of September 17, creating substantial potential dilution and selling pressure.

## Sources

- [SEC EDGAR](https://www.sec.gov/Archives/edgar/data/1658678/000121390026101505/ea0305059-s1_biostem.htm)

---
Canonical: https://techandbusiness.org/newswire/tzSkEwi6Tubn2Yf_BWmxr_
Published: 2026-09-21T00:16:26.151Z
Story chronology: 2026-09-18T12:00:00.000Z
Retrieved: 2026-09-21T02:03:35.423Z
Publisher: Tech & Business (techandbusiness.org)